Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

425 ARTÍCULOS , VIENDO DEL 286 AL 300

Genetic Risk Factors for Alzheimer Disease: Emerging Roles of Microglia in Disease Pathomechanisms

Takatori S, Wang W, Iguchi A, Tomita T.

Adv Exp Med Biol. 2019;1118:83-116. doi: 10.1007/978-3-030-05542-4_5.

Natural and Synthetic Cannabinoids for Agitation and Aggression in Alzheimer's Disease: A Meta-Analysis

Ruthirakuhan M, Lanctôt KL, Vieira D, Herrmann N.

J Clin Psychiatry. 2019 Jan 29;80(2):18r12617. doi: 10.4088/JCP.18r12617.

Huperzine-A response to cognitive impairment and task switching deficits in patients with Alzheimer's disease

Gul A, Bakht J, Mehmood F.

J Chin Med Assoc. 2019 Jan;82(1):40-43. doi: 10.1016/j.jcma.2018.07.004.

Focus on the Correlations between Alzheimer's Disease and Type 2 Diabetes

Fiore V, De Rosa A, Falasca P, Marci M, Guastamacchia E, Licchelli B, Giagulli VA, De Pergola G, Poggi A, Triggiani V.

Endocr Metab Immune Disord Drug Targets. 2019;19(5):571-579. doi: 10.2174/1871530319666190311141855.

Efficacy of rivastigmine transdermal therapy on low food intake in patients with Alzheimer's disease: The Attitude Towards Food Consumption in Alzheimer's Disease Patients Revive with Rivastigmine Effects study

Tsuno N, Mori T, Ishikawa I, Bando N, Park H, Matsumoto Y, Mori I, Tanaka M, Hirano T, Nakamura Y.

Geriatr Gerontol Int. 2019 Jul;19(7):571-576. doi: 10.1111/ggi.13644. Epub 2019 Mar 12.

Alterations in cholesterol metabolism as a risk factor for developing Alzheimer's disease: Potential novel targets for treatment

Loera-Valencia R, Goikolea J, Parrado-Fernandez C, Merino-Serrais P, Maioli S.

J Steroid Biochem Mol Biol. 2019 Jun;190:104-114. doi: 10.1016/j.jsbmb.2019.03.003. Epub 2019 Mar 13.

Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia

Rabinovici GD, Gatsonis C, Apgar C, Chaudhary K, Gareen I, Hanna L, Hendrix J, Hillner BE, Olson C, Lesman-Segev OH, Romanoff J, Siegel BA, Whitmer RA, Carrillo MC.

JAMA. 2019 Apr 2;321(13):1286-1294. doi: 10.1001/jama.2019.2000.

Diet and Inflammation in Cognitive Ageing and Alzheimer's Disease

McGrattan AM, McGuinness B, McKinley MC, Kee F, Passmore P, Woodside JV, McEvoy CT.

Curr Nutr Rep. 2019 Jun;8(2):53-65. doi: 10.1007/s13668-019-0271-4.

Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease

Egan MF, Kost J, Voss T, Mukai Y, Aisen PS, Cummings JL, Tariot PN, Vellas B, van Dyck CH, Boada M, Zhang Y, Li W, Furtek C, Mahoney E, Harper Mozley L, Mo Y, Sur C, Michelson D.

N Engl J Med. 2019 Apr 11;380(15):1408-1420. doi: 10.1056/NEJMoa1812840.

A metabolic perspective of late onset Alzheimer's disease

Ettcheto M, Cano A, Busquets O, Manzine PR, Sánchez-López E, Castro-Torres RD, Beas-Zarate C, Verdaguer E, García ML, Olloquequi J, Auladell C, Folch J, Camins A.

Pharmacol Res. 2019 Jul;145:104255. doi: 10.1016/j.phrs.2019.104255. Epub 2019 May 7.

Blood Pressure Lowering With Nilvadipine in Patients With Mild-to-Moderate Alzheimer Disease Does Not Increase the Prevalence of Orthostatic Hypotension

de Heus RAA, Donders R, Santoso AMM, Olde Rikkert MGM, Lawlor BA, Claassen JAHR; Nilvad Study Group.

J Am Heart Assoc. 2019 May 21;8(10):e011938. doi: 10.1161/JAHA.119.011938.

Intravenous immunoglobulins for Alzheimer's disease and mild cognitive impairment due to Alzheimer's disease: A systematic review with meta-analysis

Liu J, Wang LN.

Expert Rev Neurother. 2019 Jun;19(6):475-480. doi: 10.1080/14737175.2019.1620106. Epub 2019 May 23.

The efficacy and underlying mechanism of phosphodiesterase- 5 inhibitors in preventing cognitive impairment and Alzheimer pathology: A systematic review of animal studies

El-Bakly W, Wagdy O, Sobhy A, Abo Elenain O, Riad MS, El Sayed M, Tarkhan S, Yassen M, Mahmoud A, Bassiony M, Nabil N.

Behav Brain Res. 2019 Oct 17;372:112004. doi: 10.1016/j.bbr.2019.112004. Epub 2019 Jun 1.

Mitochondria- and Oxidative Stress-Targeting Substances in Cognitive Decline-Related Disorders: From Molecular Mechanisms to Clinical Evidence

Lejri I, Agapouda A, Grimm A, Eckert A.

Oxid Med Cell Longev. 2019 May 12;2019:9695412. doi: 10.1155/2019/9695412. eCollection 2019.

The effect of anti-dementia drugs on Alzheimer disease-induced cognitive impairment: A network meta-analysis

Cui CC, Sun Y, Wang XY, Zhang Y, Xing Y.

Medicine (Baltimore). 2019 Jul;98(27):e16091. doi: 10.1097/MD.0000000000016091.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias